Patient Outcomes

With healthcare budgets decreasing, market access and marketing teams at pharma companies are tasked with finding innovative ways to attract more patients and improve gross-to-nets, while keeping costs down.

Data needs vary from brand to brand. It’s critical for pharma brands to employ customized copay analytics strategies for their patient access programs.

How should pharma companies plan for if their drugs will be included in accumulator or maximizer programs? Use our interactive checklist.

Truveris’ Pharmacy Benefits Glossary of Terms provides important definitions and context to help navigate the pharmacy benefits landscape.

As biosimilars gain more popularity in the market, pharma manufacturers must think differently about launch strategies to gain market share.

If you work in the pharmacy ecosystem, you’ve probably heard buzz around “biosimilars.” What should you know about this innovative type of medication?

Many brands experience a drop in claims during January. What strategies successfully drive adherence during the beginning of the year?

Many gene therapy products are soon to be released to the market. What do payers need to know about these highly-expensive specialty drugs?

Loss of exclusivity can feel like a dramatic shift, forever changing a drug’s profitability. However, this doesn’t have to be your brand’s fate.

Looking forward to the future of pharmacy, it’s critical to understand how a specialty drug is defined, how it differs from traditional, non-specialty drugs, and how specialty is impacting employers’ benefit plan designs.  

Many Medicare patients end up not filling their high-cost prescriptions due to the Medicare coverage gap. What can manufacturers do to help Medicare patients stay adherent? 

While the goals of every copay program vary, the top 5 essential ROI metrics to track its success stay the same.